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Abstract
Background: Malaria transmission in Ethiopia is unstable and the disease is a major public health problem. Both,
p.falciparum (60%) and p.vivax (40%) co-dominantly exist. The national guideline recommends three different
diagnosis and treatment strategies at health post level: i) the use of a p.falciparum/vivax specific RDT as diagnosis
tool and to treat with artemether-lumefantrine (AL), chloroquine (CQ) or referral if the patient was diagnosed with
p.falciparum, p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum
specific RDT and AL for p.falciparum cases and CQ for the rest (paracheck pf based strategy); and iii) the use of AL
for all cases diagnosed presumptively as malaria (presumptive based strategy). This study aimed to assess the cost-
effectiveness of the recommended three diagnosis and treatment strategies in the Tigray region of Ethiopia.
Methods: The study was conducted under a routine health service delivery following the national malaria
diagnosis and treatment guideline. Every suspected malaria case, who presented to a health extension worker
either at a village or health post, was included. Costing, from the provider’s perspective, only included diagnosis
and antimalarial drugs. Effectiveness was measured by the number of correctly treated cases (CTC) and average
and incremental cost-effectiveness calculated. One-way and two-way sensitivity analyses were conducted for
selected parameters.
Results: In total 2,422 subjects and 35 health posts were enrolled in the study. The average cost-effectiveness ratio
showed that the parascreen pan/pf based strategy was more cost-effective (US$1.69/CTC) than both the paracheck
pf (US$4.66/CTC) and the presumptive (US$11.08/CTC) based strategies. The incremental cost for the parascreen
pan/pf based strategy was US$0.59/CTC to manage 65% more cases. The sensitivity analysis also confirmed
parascreen pan/pf based strategy as the most cost-effective.
Conclusion: This study showed that the parascreen pan/pf based strategy should be the preferred option to be
used at health post level in rural Tigray. This finding is relevant nationwide as the entire country’s malaria
epidemiology is similar to the study area.
Background
Malaria continues to be a global challenge with half of
the world’s population at risk of the disease. In 2006
about 250 million episodes of malaria occurred globally
with nearly a million deaths, mostly of children under
5 years of age. More than 85% of this disease burden
was concentrated in countries in Sub-Saharan Africa
(SSA). Ethiopia was one of the five main contributors to
the overall African malaria burden [1,2].
In Ethiopia, despite the long history of malaria control
since the 1950s, the disease is still a major public health
problem [3]. Though some improvements, both in mor-
tality and morbidity, have been recently achieved,
malaria has been consistently reported as one of the
three leading causes of morbidity and mortality over the
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any medium, provided the original work is properly cited.past years [4]. Malaria in Ethiopia is seasonal, predomi-
nantly unstable and focal, depending largely on rainfall
and altitude. Two transmission seasons are known:
major (September to December) and minor (April to
May). The unstable nature of malaria makes the popula-
tion non-immune and prone to focal and cyclical epi-
demics. Unlike most SSA countries where p.falciparum
almost accounts for all malaria infection, in Ethiopia,
both p.falciparum and p.vivax are co-dominant, the for-
mer accounting for approximately 60% of all cases. In
the low transmission season p.vivax increases its propor-
tion due to its relapsing nature and the seasonal drop in
p.falciparum infection [3,5,6].
In fighting against this deadly disease, early diagnosis
a n dp r o m p tt r e a t m e n ti so n eo ft h em o s tb a s i ca n d
effective global strategies [7,8]. The effectiveness of this
strategy is highly dependent on the national policy of
providing effective diagnosis and first-line antimalarial
drugs, and in the delivery system.
In 2004, Ethiopia made two important policy changes
which favoured this strategy. Firstly, it launched a com-
munity-based health care system, the Health Extension
Programme (HEP), to achieve significant essential health
care coverage. HEP is the grass-root level of the primary
health care (PHC) through the provision of two health
extension workers (HEWs) in a health post (HP) at tabia
(sub-district) level to serve approximately 5,000 inhabi-
tants. HEWs are high school graduated women with one
year of training on the components of the HEP pro-
grammes. HEP is a package of sixteen basic health com-
ponents. All components of the programme comprise
health promotion and prevention activities except the
malaria intervention which, in addition, incorporates
diagnosis and treatment [9]. HEP has been successfully
implemented throughout the country including Tigray.
Currently, there are more than 1,220 health extension
workers in Tigray and the coverage has increased from
30% in 2006/7 to above 70% in 2007/8 [10].
Secondly, the country has made two changes on its
national malaria diagnosis and treatment guideline.
Malaria confirmatory diagnosis using rapid diagnostic
tests (RDTs) replaced presumptive diagnosis, while
maintaining the latter approach where the former is
unavailable [8]. A presumptive malaria case is a patient
who exhibits fever or history of fever within the past
48 hrs in the absence of clear symptoms indicating
alternative causes of fever. RDTs are tests based on the
detection of antigens released from the malaria parasites
in lysed blood [11]. The second change included a shift
in the treatment of p.falciparum from monotherapy
sulphadoxine-pyrimethamine (SP) to artemisinin-based
combination therapy (ACT), namely artemether-
lumefantrine (AL), while keeping chloroquine (CQ) for
treating p.vivax. The guideline recommends three
different diagnosis and treatment strategies: i) if malaria
is diagnosed with a falciparum-specific and pan-specific
device, treat p.falciparum cases with AL, p.vivax with
CQ and refer negatives to a higher level; ii) if malaria is
diagnosed with only a p.falciparum-specific device, treat
positive (p.falciparum) cases with AL and all the
remaining with CQ; and iii) if malaria is diagnosed
presumptively, treat all suspected cases with AL [8].
P.falciparum positive patients for whom AL is contra-
indicated have to be treated with quinine and patients
with one or more signs and symptoms of severity should
be referred immediately to the nearest higher facility.
In the study year, 2007, on top of the presumptive
diagnosis, two types of RDTs were in use at the health-
post level in the study area: parascreen pan/pf (Zephyr
Biomedical, Goa, India) and paracheck pf (Orchid Bio-
medical Systems, Goa, India); the former is able to iden-
tify both p.falciparum and p.vivax while the latter
targets only p.falciparum. While paracheck pf was the
commonly used RDT at health post level since 2004,
parascreen pan/pf had been recently introduced.
Several studies on RDT cost-effectiveness (CE) have
been conducted in the past years. Most of these studies
were focused in areas of high malaria transmission and
p.falciparum. Almost all were comparing potentially
similar types of RDTs either with microscope and/or
presumptive diagnosis [12-18]. However, none of them
are similar to the Ethiopia malaria epidemiological con-
text and to the current national diagnosis and treatment
strategies.
Therefore, this operational research was designed to
assess the cost-effectiveness of the recommended three
diagnosis and treatment strategies in the Tigray region
of Ethiopia. This will provide evidence to assist decision
makers on which strategy is the most appropriate in the
region
Methods
Study area
Tigray regional state is located in northern Ethiopia and
is divided into 47 woredas (districts). The region has
approximately 4.3 million inhabitants most of whom
(81.2%) live in rural areas [19]. The majority of the
population works in agriculture. Famine and drought
are regular occurrences in the region. As in the rest of
Ethiopia, malaria transmission in Tigray is very seasonal
and occurs mainly at altitudes up to 2,200 meters above
sea level (masl). Around 65% of the population is at risk
of malaria and the disease was the number one cause of
outpatient cases, admissions and deaths. In 2006, it
accounted for 28% of all the patients treated in the
regions’ health facilities [20]. Previous efforts to control
the problem have included insecticide residual spraying
and environmental management. Since 2005,
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covering all malarious villages.
The health system in Tigray is essentially the same as
in the rest of Ethiopia, i.e., a four-tier system with Pri-
mary Health Care Units (PHCUs) at the grass-roots
level. There are five zone-level hospitals, six district hos-
pitals and one referral hospital in Mekelle, the capital.
Sampling procedure
In order to capture epidemiological variations, the study
was stratified into the three commonly known malaria
strata in the country: stratum-I (<1000 masl), stratum-II
(1000-1500 masl) and stratum-III (1501-2000 masl).
A district in a given stratum with a high number of vil-
lages was selected to represent its respective stratum.
Four districts were selected: Kafta-Humera, Tahtay-
Adiyabo, and Mereb-leke plus Raya-Azebo from strata I,
II, and III respectively. Two districts were included in
the strata III for being the largest strata. The districts
populations ranged from 91,379 in Tahtay-Adiyabo to
136,039 in Raya-Azebo. In all the study districts, malaria
has constituted a leading cause of the disease burden
over years. For instance, in 2007/8 it accounted for 21%-
28% of outpatient visits in the districts [20].
The study was conducted under a routine HEP service
following the national malaria diagnosis and treatment
guideline during the main transmission months of 2007.
Half of the health posts (7-8) in each district were ran-
domly selected.
Patient enrolment and management
All diagnosis and treatment procedures were done by
the HEWs under routine conditions following the
national guideline. HEWs (enumerators) were trained
with a major focus on how to interpret the result of the
newly introduced parascreen pan/pf device, blood film
preparation and data collection. No additional training
was given on paracheck pf as it had been used for years.
Every suspected malaria case, who presented to a
HEW either at a village or health post, was included.
Following the national malaria guideline, patients were
excluded if they: i) exhibited signs and symptoms of
severe malaria or any other severe disease, ii) had taken
antimalarial drugs (AL or quinine) within the previous
two weeks, and iii) were infants under three-months-old
or were pregnant mothers during their first trimester for
whom AL is contraindicated.
Previous years have shown a slide positivity rate (SPR)
of approximately 30% in the high-transmission season
[20]. For this anticipated SPR, with a confidence level of
95%, an absolute precision of five percentage points
(25% to 35%) and a design effect of two), the required
sample size was 646 patients for each stratum.
Patient history, including demographic data, signs and
symptoms related to current illness (chief complaint)
and medication, was collected. A finger-pricked blood
sample from each subject was taken for the two types of
RDTs, according to the RDT manufacturer’s instructions
(leaflet enclosed within the kit) and a blood film (thick
and thin) for the microscope examination following the
World Health Organization (WHO) guideline [21].
Patients were treated for malaria if one of the RDTs was
positive.
The reference expert microscopy
Performance of the three alternative diagnostic and
treatment strategies were calculated vis-à-vis the light
microscopy. Blood films were stained with 3% Giemsa
stain and examined by two independent (first and sec-
ond) microscopists using ×1000 oil immersion following
the WHO guideline [21]. The independent readings
were compared for concordance of presence or absence
of asexual/sexual forms of plasmodium and its species.
A third senior microscopist examined discordant slides
and his/her findings taken as true diagnostic outcome.
A negative was declared after 200 microscopic fields
read without finding a parasite. The first and the second
microscopists were unaware of the RDT results and the
third reader was blind to the results of both the RDTs
and the preceding microscopists.
Data analysis
The cost-effectiveness (CE) of the three different diag-
nosis and treatment strategies was compared. The stra-
tegies included: i) the use of parascreen pan/pf as
diagnosis tool and to treat with AL, CQ or referral if
the patient was diagnosed with p.falciparum, p.vivax or
no malaria respectively (parascreen pan/pf based strat-
egy); ii) the use of paracheck pf and AL for p.falciparum
cases and CQ for the rest (paracheck pf based strategy);
and iii) the use of AL for all cases diagnosed presump-
tively as malaria (presumptive based strategy). All data
were entered in to Microsoft Excel version 8. Effective-
ness was calculated using Epi Info™ version 3.5 [22]
and the cost and cost-effectiveness were calculated
using Microsoft Excel 8.
Costing
Costing was undertaken from the provider’s perspective
(government) at the health post level and restricted only
to the first visit of a patient. At this facility level, the
entire malaria diagnosis and treatment service is free of
charge.
Costing considered only diagnosis and antimalarial
drugs because the fixed costs (infrastructure, supervision,
training and HEWs salaries) were assumed not to differ
among the comparative strategies. The cost of these
i t e m si sa l s os h a r e dw i t ho ther health programmes.
RDT provision, compared to presumptive diagnosis, com-
prises other operational and management costs at
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ever, this cost was reasonably assumed as similar for both
RDT-based strategies and traded-off with the expenditure
reduction on drug management and transport as RDT
application decreased the amount of AL needed. RDT
costing was at the manufacturer’s price and was calcu-
lated as the total number of presumptive patients multi-
plied by the unit price of each type of RDT kit (including
lancets, swabs, pipette, buffer solution and desiccant).
AL costing was calculated at the manufacturer’sc o s t
(but not CQ) as it has been provided at no profit, as per
the special pricing agreement between WHO and the
manufacturer [23]. Antimalarial drug cost was calculated
following the malaria diagnosis and treatment guideline
at the peripheral level. Being age dependent, the number
of cases in each treatment regimen was multiplied by
the cost of the respective treatment course of either AL
or CQ. Unit costs were obtained from the Tigray Health
Bureau (THB) pharmacy unit for the year 2007. The fol-
lowing items were not including in costing: RDT read-
ing time, RDT wastage and RDT training cost.
Effectiveness indicator and cost-effectiveness measure
RDTs, highly specific and less sensitive compared to
presumptive diagnosis, are mainly introduced since pre-
sumptive treatment is non-specific while it is 100% sen-
sitive. Therefore, there is a need to balance the risk
between improving specificity (excluding non-malaria
cases) and reducing sensitivity (missing malaria cases)
while replacing presumptive with RDTs. Taking this
into account, we selected the number of correctly trea-
ted cases (CTC) as the measure of effectiveness on the
basis of the malaria diagnosis and treatment strategies.
This indicator accommodates both concerns: detecting
the malaria cases (sensitivity) and excluding the non-
malaria cases (specificity) supporting the public health
goal of properly managing all causes of illness. In low
malaria prevalence areas such as Tigray [24], all malaria
infections, even with low-level parasitaemia, are asso-
ciated with clinical illness in all age groups. In such
malaria epidemiology, there is no evidence if missing
malaria cases is more or less dangerous than missing
non-malaria cases or the vice-versa. Therefore, it was
assumed that the weight of correctly or mistakenly treat-
ing cases of any disease including malaria was equal.
A non-malaria case identified by the parascreen pan/pf
was referred to a higher health facility level - this meant
that this patient was correctly treated. The number of
correctly treated cases was then calculated as the num-
b e ro ft r u ep o s i t i v e sp l u st h en u m b e ro ft r u en e g a t i v e s
cases.
Cost-effectiveness was estimated as average cost-
effectiveness ratio (ACER) and incremental cost-effec-
tiveness ratio (ICER). ACER was calculated as a cost of
diagnosis and treatment of a given strategy divided by
the number of CTCs. To find out if an extra cost in a
strategy produced an extra effect (health benefit), ICER
analysis was conducted where the strategies were ranked
by increasing cost and then the additional cost in one
strategy was divided by the additional CTCs [25].
Sensitivity analysis
Sensitivity analysis for selected parameters for which the
cost-effectiveness is more sensitive was conducted.
Changes in some variables may have skewed some find-
ings; to allow for this, a one-way sensitivity analysis was
carried out on changes in AL cost and SPR. A reduction
in cost for AL was incorporated into the analysis since
the price of AL has been constantly decreasing through-
out the last few years (even though drug resistance may
n e c e s s i t a t et h ep u r c h a s eo fm o r ee x p e n s i v ea n t i m a l a r i a l
drugs in the future). We did not consider changes on
RDT price, as it seems unlikely to drop in the near
future for at least two possible reasons: firstly, there is a
huge gap between the demand and supply - for instance,
in 2006, only 16 million RDTs were distributed while
80 million courses of ACTs were used [1]. Secondly,
despite the potential high demand, the prices have been
kept constant in the last years.
Change in SPR as a function of seasonal variation is
inevitable. We considered a minor transmission season
(the point estimate was of the major season), whilst
assuming the diagnostic performance remained con-
stant. A two-way sensitivity analysis was also carried out
at a reduced AL cost during a low transmission season.
Ethical clearance
Ethical clearance was obtained from Tigray Health
Bureau, Mekelle, Ethiopia. District Health Offices were
informed of the study and its purposes. The purpose of
the study was explained to the participants. Verbal con-
sent was obtained from (patient/patient’sg u a r d i a n )a s
the majority of the rural population is illiterate. No
patient refused to participate. Confidentiality of patient
identity was maintained for every enrolled patient by
assigning a unique identification number that was
labelled on the RDT devices, blood film slides, data col-
lection forms and database.
Results
Characteristics of the subjects
In total 2,422 subjects from all three strata and 35
health posts were enrolled in the study. Overall, 26.63%
(n = 645), 28.0% (n = 677) and 45.42% (n = 1100) of the
subjects were from strata I, II and III, respectively. In
total, 37.2% (n = 901) were female, 13.96% (n = 338)
were children aged under five years, 18.66% (n = 452)
aged between 5-14 years and the remaining 67.38% were
15 years or above. The age of the study subjects ranged
from three months to 85 years with a mean of 24.18
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treatment within one day since the onset of illness.
Most of the patients (86.21%) appeared with fever and
the remaining with a history of fever.
Microscope result
The microscope examination of thick blood smear
showed a crude (all species and all stages) SPR of
27.29% (n = 661) with 68.53% (n = 453) of the positive
samples being p.falciparum (+/-gametocytes, gametocyte
alone and mixed) and 31.47% (n = 208) p.vivax (+/-
gametocytes) (Table 1). The stratified SPR was 46.51%,
26.88% and 16.27% with a p. falciparum proportion of
68%, 69.78% and 69.77% for stratum I, II and III, respec-
tively. There were 27 cases of gametocytes, out of which
26 were in the presence of asexual stage. There was
only one mixed infection of p.falciparum and p.vivax.
From the operational point of view, all these 28 cases
were considered as p.falciparum. There was one case of
p.vivax in the presence of gametocytes which was con-
sidered as p.vivax.
Cost analysis
The unit cost was US$ 0.59 (US$ = 9.00 Ethiopian birr
for 2007) for the paracheck pf kit, US$1.05 for the para-
screen pan/pf kit and US$ 0.03 for a pair of gloves.
A treatment course of AL cost US$ 0.60, 1.20, 1.80 and
2.40 according to the treatment regimen (age) group.
Each CQ tablet cost US$0.006.
The cost analysis indicated that the presumptive-based
strategy (BS) was higher by 27.69% and 46.1% than the
cost of the parascreen-BS and paracheck-BS, respec-
tively. In the RDT-BS, the tests’ cost accounted for the
majority of the expenditure, 55.52% in paracheck-BS
and 72.08% in parascreen-BS. AL constituted 41%,
27.65% and 100% of the total cost of paracheck-BS,
parascreen-BS and presumptive-BS, respectively. Cost of
chloroquine was insignificant which was 3.48% in para-
check-BS and less than 1% in parascreen-BS.
Effectiveness indicator and cost-effectiveness
Out of the 661 malaria and 1761 non-malaria cases,
parascreen-BS correctly treated 88.48% cases (377
p.falciparum,1 5 5p.vivax and 1611 negatives) (Table 2).
It failed to identify 11.52% patients, out of which 5.33%
were malaria patients (76 p.falciparum and 53 p.vivax)
who would have been left untreated (false negatives)
and 6.19% (97 false p.falciparum and 53 false p.vivax)
would have been incorrectly given antimalarial drugs
(Table 1). Paracheck-BS correctly treated 23.95% cases
(402 p.falciparum and 178 p.vivax) and mislabelled
76.05% (n = 1842). Out of these, 3.34% were malaria (51
p.falciparum classified as p.vivax and 30 p.vivax as p.fal-
ciparum) and 72.70% (n = 1761) were non-malaria (114
cases classified as p.falciparum out of which 11 were
p.vivax and 1647 as p.vivax when they were not). The
presumptive-BS captured all the p.falciparum,( 1 8 . 7 % ,
n = 453) but mistreated 1969 cases (81.30%) as
p.falciparum, out of which 8.59% (208) were p.vivax and
72.71% were non-malaria (Table 2).
The CE analysis showed that the parascreen-BS was
the most cost-effective with ACER US$ 1.69/CTC fol-
lowed by US$ 4.66/CTC for the paracheck-BS and US
$11.08/CTC for the presumptive-BS (Table 3). ICER
analysis was conducted to find out whether this addi-
tional cost was worth paying to get the added effect.
Presumptive-BS was highly dominated (less effect for
more money) by parascreen-BS. Therefore, the ICER
calculation was limited to parascreen-BS over para-
check-BS. At the base case, the additional cost on para-
screen-BS over paracheck-BS would be able to treat an
Table 1 Summary result of the comparison between the
expert microscopy and the RDTs, Tigray, Ethiopia, 2007
Expert
Microscope
Paracheck pf Parascreen pan/pf Total
(microscope)
Positive Negative Positive Negative
P.falciparum
Positive 402 51 377 76 453
Negative 114 1855 97 1872 1969
Total 516 1906 474 1948 2422
P.vivax
Positive - - 155 53 208
Negative - - 53 2161 2214
Total - - 208 2214 2422
P.falciparum positive is: asexual +/- sexual, asexual +/- p.vivax; P.vivax positive
is: asexual +/- sexual; Paracheck pf negative is meant no-p.falciparum;
Parascreen pan/pf p.vivax positive meant non p.falciparum malaria.
Table 2 Effectiveness and cost ($US) of the three
different diagnostic strategies, Tigray, Ethiopia, 2007
Description Different treatment strategies
Presumptive
n (%)
Paracheck-
BS
n (%)
Parascreen-
BS
n (%)
Correctly treated p.
falciparum cases
453 402 377
Correctly treated p.vivax
cases
0 178 155
Correctly treated non-
malaria cases
0 0 1611
Total correctly treated cases 453 (18.70) 580 (23.95) 2143 (88.48)
Test Cost 0 1501.64
(55.52)
2615.76
(72.08)
AL cost 5017.2 1108.80
(41.00)
1003.20
(27.65)
CQ cost 0 94.05(3.48) 9.80(0.27)
Total cost 5017.20 2704.49 3628.76
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incremental cost of US$0.59/patient.
Sensitivity analysis
Taking into account the AL cost in the International
Drug Price Indicator (2008v e r s i o n )t h a ts h o w e da
reduction of 32.8% (lowest dose), 33.25% (for the middle
doses) and to 36.9% (adult dose) [26], a sensitivity analy-
sis revealed a high reduction in the cost of the presump-
tive-BS by 37.14%, in paracheck-BS by 14.93% and in
parascreen-BS by 10.05% (Table 4). The base case ACER
was improved by 36.20% (from US$11.08 $US7.05) in
presumptive-BS, by 14.81% (from US$ 4.66 to $US 3.97)
in paracheck-BS and by 10.05% (from US$ 1.69 to $US
1.52) in parascreen-BS. Despite the significant drop in
ACER, presumptive-BS was still dominated by para-
screen-BS. The ICER of parascreen-BS over paracheck-
BS was increased from $US0.59 to $US0.62 for each
additional 1563 correctly treated cases.
The sensitivity analysis at 15% SPR during the minor
transmission season with 35% p.falciparum to 65%
p.vivax, with no change in the diagnostic performance
of the strategies to the base case, showed a reduction in
the proportion of correctly treated cases in the pre-
sumptive and paracheck-BS. The proportion of CTC
was, however, increased in the parascreen-BS strategy
(Table 4). The base case ACER decreased in parascreen-
BS (from $US 1.69 to $US 1.29/CTC) and increased in
the paracheck (from $US 4.66 to $US 6.11/CTC) and
presumptive-BS (from $US 11.08 to $US 39.51/CTC)
per correctly treated case. This illustrated that the cost-
effectiveness increased by 23.67% in the parascreen-BS,
decreased in the paracheck-BS by 31.12% and deterio-
rated significantly in the presumptive-BS by 258%. Since
presumptive-BS was dominated, the IECR was recalcu-
lated as parascreen-BS over paracheck-BS. The base
case of $US 0.59 dropped to $US 0.51/additional cor-
rectly treated case (Table 4).
A two-way sensitivity analysis (Table 5) at reduced cost
of AL during the minor transmission season showed an
increase in the ACER from $US 4.66 to $US 5.75 and
from $US 11.08 to $US 25.14 in the paracheck-BS and
presumptive-BS, respectively, while it dropped from $US
1.69 to $US 1.25 in the parascreen-BS. The two-way sen-
sitivity analysis showed that presumptive-BS continued to
be dominated by parascreen-BS.
Discussion
This is, to our knowledge, the first empirical study in
Ethiopia evaluating the economic implications of the
malaria diagnostic and treatment strategies currently
implemented in the country. It is also a unique study in
that it compared two RDTs targeting different plasmo-
dium-specific antigens (p.falciparum and p.vivax vs. only
p.falciparum) from an operational point of view.
This study has supported two central facts regarding
the malaria transmission pattern in the region: firstly,
our result of SPR (27.3%) and species composition of
Table 3 Average and incremental cost-effectiveness ratios among the three diagnosis strategies, Tigray, Ethiopia, 2007
Diagnostic based strategy Cost Correctly treated cases ACER Incremental cost Incremental effect ICER Remark
Paracheck 2704.5 580 4.66 - - -
Parascreen 3628.8 2143 1.69 924.27 1563 0.59
Presumptive 5017.2 453 11.08 1388.44 -1690 -0.82 dominated
Table 4 Sensitivity analysis at reduced AL cost and low-transmission for three malaria diagnostic strategies, Tigray,
2007
At reduced AL price Low transmission season (15% SPR)
Comparison Strategy Strategies
Paracheck-BS Parascreen-BS Presumptive-BS Paracheck-BS Parascreen-BS Presumptive-BS
Base case cost 2704.49 3629.76 5017.20 2704.49 3629.76 5017.2
Total new cost 2300.80 3264.20 3192.70 1926.05 2908.56 5017.20
Cost change within strategy 403.69 364.56 1886.50 778.44 720.20 0
Cost change in (%) (14.93) (10.05) (37.14) (28.78) (19.85) 0
Correctly treated cases (n, %) 580 (23.95) 2143 (88.48) 453 (18.7) 315 (13.01) 2253 (93.02) 127 (5.24)
ACER at reduced AL and SPR 3.97 1.52 7.05 6.11 1.29 39.51
ACER Change from base case, % (14.81) (10.06) (36.2) (+31.1) (23.67) (+258)
Cost difference b/n strategy 0.00 963.40 -71.50 0.00 982.51 2108.64
Effect difference b/n strategy 0.00 1563.00 -1690 0.00 1938 -2124
ICER - 0.62 dominated - 0.51 dominated
+ ACER indicates higher value than the base case.
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sistent with the commonly quoted statistics in serial
reports of the THB [20]. Secondly, it has confirmed that
malaria in the region varies from place to place due to
differing altitude. The SPR was 46.51% for the lower
stratum, 26.88% for the middle, and 16% for the
highest stratum whilst showing a similar proportion of
p.falciparum to p.vivax (range 68%-69.78%). As many
other studies have indicated [17,27,28], this research has
also revealed that the shift from presumptive-BS to
RDT-BS is clearly of significant benefit in the era of
ACT. In our context where malaria transmission is low,
the likelihood of a fever episode being due to malaria,
even during the peak transmission season, is on average
30%. Approximately one-third of this corresponds to p.
vivax, increasing to two-thirds during the minor trans-
mission season. The prevalence and proportion of the
species bitterly challenges the presumptive-BS strategy
as it leads to mistreat numerous p.vivax and false non-
malaria cases. The need of using RDT-BS is therefore
not debatable. Instead, the discussion should be tailored
toward which type of RDT is the more cost-effective to
ensure the maximum number of patients receive appro-
priate treatment. Accordingly, parascreen-BS was found
to be the more cost-effective. The ICER showed that, if
we invest in parascreen-BS instead of paracheck-BS, we
can properly manage 65% (1563) additional cases for as
little as $ 0.59/patient. If we spend on presumptive-BS
instead of parascreen-BS, the cost rises to US$ 0.82/
patient (highly dominated). In fact, the cost-effectiveness
of RDT-BS over presumptive-BS was partially increased
at the expense of some missed malaria cases, since the
RDTs are less sensitive than the presumptive-BS. We
are also aware that if the effectiveness measure would
have been only malaria cases, the paracheck-BS would
have been the more cost-effective. However, the health
benefit with the parascreen-BS is higher as more non-
malaria cases get appropriate treatment and the saving
is greater by avoiding over prescription. Over-treatment
of malaria results in considerable morbidity and mortal-
ity by delaying the correct treatment of non-malaria ill-
ness and by contributing to the development and spread
of antimalarial resistance strains.
The sensitivity analysis showed that the cost-effective-
ness of the strategies varied depending on the season
and AL cost. With the AL price drop, all alternatives
improved their cost-effectiveness; however, in the low-
transmission season, both the paracheck-BS and the pre-
sumptive-BS suffered while the parascreen-BS still
improved. This shows that parascreen-BS is even more
cost effective with reduced AL cost and during low-
transmission season, which is the longest period of the
year (December-August). Though no sensitivity analysis
was made with regard to the different malaria strata, the
higher the elevation, the lower the SPR makes para-
screen pan/pf still more cost effective. Studies con-
ducted in semi-immune populations have shown a
higher cost effectiveness of RDTs in children <5 years
compared to other age groups [14,29]. In our case,
where all age groups share practically equal risk of
malaria, this sensitivity analysis was not relevant.
Though the literature on the cost-effectiveness of
RDTs has been growing in the last years [12-18,28], no
comparable study designs to ours were found. The focus
of all the studies has been on one type of plasmodium-
specific RDT, either p.falciparum specific [13,14,17] or
in combination with p.vivax [12,16]. Our study com-
pared both types of plasmodium-specific RDTs at the
same time.
Methodological considerations
There are some considerations to take into account
which can potentially affect the findings of this research.
Firstly, our study was limited to the health-provider per-
spective at the rural health post level. If a full societal
perspective had been used to capture the distributional
impact of the intervention, the epidemiological and eco-
nomical advantages of the best RDT-BS might have been
even higher. One limitation was that the study design did
not allow us to capture whether HEWs complied with
the guideline in their therapeutic decision-making. The
HEW prescription report might not show the actual
practice. Experience from the field and recent studies
have shown that health workers are prescribing antima-
larial drugs regardless of negative test results [17,30-35].
Cost calculation did not include the RDT reading
time, RDT wastage and RDT training cost. The former
is difficult to measure because the reading time might
include attending several patients. RDTs could be
wasted for different reasons such as poor transport,
Table 5 A two-way sensitivity cost-effectiveness analysis at reduced cost of AL during low-transmission season, Tigray,
2007
Diagnostic strategies Cost Correctly treated cases ACER Incremental cost Incremental effect ICER
Paracheck-BS 1812.61 315 5.75 0 0 0
Parascreen-BS 2806.27 2253 1.25 993.66 1938 0.51
Presumptive-BS 3193.00 127 25.14 386.73 -2126 -0.18 (dominated)
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estimate these wastage’s costs would have been extre-
mely difficult. The few hours training on RDT, which it
is a long-term investment, made also difficult to allocate
the cost to the patients. In our study, weights to malaria
and non-malaria cases were assumed to be equal since
our study population is non-immune. In some studies
conducted in semi-immune populations, more weight
has been given to non-malaria patients because malaria
severity is less in adults [13,28].
Conclusions
The study has shown that the most cost-effective strat-
egy was the one which used parascreen pan/pf in the
treatment of malaria. The finding is relevant not only
for Tigray region but also for the whole country, since
malaria epidemiology follows a similar pattern nation-
ally. Since 2008, the only available strategies at the
health post level in the country have been the paracheck
pf-BS and presumptive-BS. Our finding, pointing the
superiority of the parascreen pan/pf based strategy, call
decision-makers to reconsider this policy.
These results will be, however, pertinent only if an
adequate supply of RDT and first-line antimalarial drugs
at the health-post level are ensured and if HEWs com-
ply with test results. Furthermore, and importantly,
proper management of RDTs and adequate training and
continuous supervision of HEWs should also be main-
tained. Finally, a study that captures the final health out-
come of malaria diagnosis and treatment strategies and
assesses HEWs’ compliance with test results should be
top research priorities in the region
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